Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

C-Type Natriuretic Peptide and Cardiovascular-Renal Protection in Sepsis.

Hypertension (Dallas, Tex. : 1979)·2026

Same author

The Concise Guide to PHARMACOLOGY 2025/26: Catalytic receptors.

British journal of pharmacology·2025

Same author

Effects of physiological doses of atrial natriuretic peptide on lipolysis, ketogenesis, and glucose metabolism in men.

American journal of physiology. Endocrinology and metabolism·2025

Same author

C-Type Natriuretic Peptide: Protecting the Aorta.

Arteriosclerosis, thrombosis, and vascular biology·2025

Same author

Significance of common genetic variants associated with non-ischaemic cardiomyopathy in the general population.

European journal of heart failure·2025

Same author

NPA7: A Dual Receptor Activating Peptide That Inhibits Cardiac Oxidative Stress.

Hypertension (Dallas, Tex. : 1979)·2025

Same journal

The Hedgehog Pathway Effector Smoothened Exhibits Signaling Competency in the Absence of Ciliary Accumulation.

Chemistry & biology·2017

Same journal

DIVERSE System: De Novo Creation of Peptide Tags for Non-enzymatic Covalent Labeling by In Vitro Evolution for Protein Imaging Inside Living Cells.

Chemistry & biology·2015

Same journal

Differential Regulation of Specific Sphingolipids in Colon Cancer Cells during Staurosporine-Induced Apoptosis.

Chemistry & biology·2015

Same journal

Synthetic Peptides as cGMP-Independent Activators of cGMP-Dependent Protein Kinase Iα.

Chemistry & biology·2015

Same journal

Unraveling the B. pseudomallei Heptokinase WcbL: From Structure to Drug Discovery.

Chemistry & biology·2015

Same journal

Vitamin C as Cancer Destroyer, Investigating Sulfhydration, and the Variability in CFTR Interactome.

Chemistry & biology·2015

See all related articles

Search research articles

Related Experiment Video

Updated: May 25, 2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

RNA-based therapeutics: current progress and future prospects.

John C Burnett¹, John J Rossi

¹Department of Molecular and Cellular Biology, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.

Chemistry & Biology

|January 31, 2012

Summary

This summary is machine-generated.

RNA therapeutics like small interfering RNAs (siRNAs), aptamers, and ribozymes show promise for treating diseases. Advances in delivery and chemical modifications are overcoming challenges like instability and immunogenicity for broader clinical success.

More Related Videos

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

Related Experiment Videos

Last Updated: May 25, 2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Published on: March 13, 2018

Area of Science:

Biotechnology
Molecular Medicine
Drug Development

Background:

Biological drugs have expanded therapeutic targets, with RNA-based therapeutics showing significant potential.
Emerging RNA drugs, including ribozymes, aptamers, and small interfering RNAs (siRNAs), highlight RNA's versatility.
Challenges such as RNA instability, immunogenicity, and delivery efficiency have impacted clinical progress.

Purpose of the Study:

To review the clinical results of siRNA, RNA aptamer, and ribozyme therapeutics.
To discuss the prospects for future successes of RNA-based therapies.
To highlight the impact of synthetic delivery carriers and chemical modifications on overcoming RNA drug limitations.

Main Methods:

Review of clinical trial data for siRNA, RNA aptamer, and ribozyme therapeutics.
Analysis of recent advancements in synthetic delivery carriers for RNA drugs.
Examination of chemical modification strategies to improve RNA stability and reduce immunogenicity.

Main Results:

Promising results from recent clinical trials indicate potential for overcoming existing barriers.
Improved delivery systems and chemical modifications are enhancing the efficacy and safety of RNA therapeutics.
The review focuses on the clinical outcomes and future potential of specific RNA-based drug classes.

Conclusions:

Despite inherent challenges, RNA-based therapeutics are progressing clinically.
Advancements in delivery and modification technologies are crucial for the success of RNA drugs.
RNA therapeutics hold significant promise for treating a wide range of human diseases.